| 1 |
33866774 | Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors. | 2022 Jan |
1 |
| 2 |
33430081 | Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection. | 2021 Jan 8 |
1 |
| 3 |
33820392 | Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis. | 2021 Apr |
1 |
| 4 |
34124273 | Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways. | 2021 |
1 |
| 5 |
34365776 | Comparison of the Effects of Various Antidiabetic Medication on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus. | 2021 Aug |
1 |
| 6 |
34686738 | Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system. | 2021 Oct 22 |
1 |
| 7 |
34697593 | Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial. | 2021 |
1 |
| 8 |
32535099 | The vasodilatory effect of gemigliptin via activation of voltage-dependent K+ channels and SERCA pumps in aortic smooth muscle. | 2020 Sep 5 |
2 |
| 9 |
32615723 | Gemigliptin Inhibits Interleukin-1β-Induced Endothelial-Mesenchymal Transition via Canonical-Bone Morphogenetic Protein Pathway. | 2020 Jun |
1 |
| 10 |
31733799 | Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus. | 2019 Dec |
1 |
| 11 |
29147952 | Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells. | 2018 Jun |
1 |
| 12 |
29285650 | Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells. | 2018 Feb |
1 |
| 13 |
29803171 | Protective effects of gemigliptin against type II collagen degradation in human chondrocytes. | 2018 Aug |
2 |
| 14 |
30249366 | Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers. | 2018 Oct |
1 |
| 15 |
27619558 | Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study). | 2017 Jan |
1 |
| 16 |
27868366 | Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes. | 2017 Mar |
2 |
| 17 |
28026912 | Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study). | 2017 May |
2 |
| 18 |
28058753 | Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study). | 2017 Jun |
1 |
| 19 |
28982310 | The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells. | 2017 Oct |
2 |
| 20 |
27098503 | Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice. | 2016 Jun |
1 |
| 21 |
27298192 | Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. | 2016 Oct 5 |
1 |
| 22 |
27766241 | Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus. | 2016 Oct |
2 |
| 23 |
25350224 | Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. | 2015 Feb |
2 |
| 24 |
25661535 | The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms. | 2015 Apr 15 |
2 |
| 25 |
26021829 | Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial. | 2015 May 29 |
1 |
| 26 |
26187356 | Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation. | 2015 Oct |
4 |
| 27 |
26297911 | A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression. | 2015 Nov 1 |
1 |
| 28 |
26391252 | Gemigliptin, a dipeptidyl peptidase-4 inhibitor, inhibits retinal pericyte injury in db/db mice and retinal neovascularization in mice with ischemic retinopathy. | 2015 Dec |
2 |
| 29 |
24304170 | Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. | 2014 Jun |
3 |
| 30 |
24627290 | Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects. | 2014 Jun |
3 |
| 31 |
24641348 | Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444). | 2014 Oct |
2 |
| 32 |
24962635 | Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers. | 2014 Sep |
1 |
| 33 |
23170990 | A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. | 2013 May |
2 |
| 34 |
23320436 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. | 2013 Jun |
2 |
| 35 |
23771499 | Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry. | 2013 Oct |
2 |
| 36 |
22192641 | Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers. | 2012 Jan |
2 |
| 37 |
22534255 | Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers. | 2012 May |
3 |
| 38 |
20977584 | A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. | 2010 Dec |
2 |
| 39 |
20002082 | Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. | 2009 Dec |
1 |
| 40 |
19014837 | Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study. | 2008 Oct |
1 |